Sino Biopharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Sino Biopharmaceutical has a total shareholder equity of CN¥38.2B and total debt of CN¥12.2B, which brings its debt-to-equity ratio to 32%. Its total assets and total liabilities are CN¥63.6B and CN¥25.4B respectively. Sino Biopharmaceutical's EBIT is CN¥5.4B making its interest coverage ratio -46.8. It has cash and short-term investments of CN¥12.6B.
Key information
32.0%
Debt to equity ratio
CN¥12.21b
Debt
Interest coverage ratio | -46.8x |
Cash | CN¥12.56b |
Equity | CN¥38.17b |
Total liabilities | CN¥25.43b |
Total assets | CN¥63.60b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: SBMF.F's short term assets (CN¥23.8B) exceed its short term liabilities (CN¥22.6B).
Long Term Liabilities: SBMF.F's short term assets (CN¥23.8B) exceed its long term liabilities (CN¥2.8B).
Debt to Equity History and Analysis
Debt Level: SBMF.F has more cash than its total debt.
Reducing Debt: SBMF.F's debt to equity ratio has increased from 9.1% to 32% over the past 5 years.
Debt Coverage: SBMF.F's debt is well covered by operating cash flow (40.8%).
Interest Coverage: SBMF.F earns more interest than it pays, so coverage of interest payments is not a concern.